Heron Therapeutics signs multi-product license deal with Long Grove Pharmaceuticals
The Delaware companies entered a Development and License Agreement on September 23, 2026 covering US distribution rights, with terms disclosed in a September 29 SEC filing.
Heron Therapeutics, Inc. disclosed in an 8-K filed September 29, 2026 that it entered into a multi-product Development and License Agreement on September 23, 2026 with Long Grove Pharmaceuticals, LLC and Capstone Development Services Company, LLC, both Delaware limited liability companies. The agreement grants Heron an exclusive, sublicensable license from Long Grove to import, distribute, sell and market certain products in the United States and its territories, commonwealths and possessions, along with a non-exclusive worldwide manufacturing license for products sold in that territory, and requires the parties to collaborate on developing and commercializing the products.1
Capstone's role in the agreement is limited to providing certain exclusivity covenants and backstop obligations.1
Under the deal, Heron will pay Long Grove regulatory milestone payments, sales-based milestone payments, and royalty payments, and will reimburse Long Grove for certain expenses.1
The agreement runs for an initial term of ten years from the first commercial sale of any product, with automatic two-year renewal terms, and either party may terminate it under conditions the filing describes as customary for this type of agreement.1
Heron said the full text of the agreement does not appear in the 8-K itself; a complete copy is planned to accompany the company's upcoming quarterly report covering the period through September 30, 2026.1
The filing was signed by Ira Duarte, Heron's Executive Vice President and Chief Financial Officer, dated September 29, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.